ProPhase Labs, Inc. (“ProPhase” or the “Company”), a diversified life sciences and diagnostics company, today announced that its common stock has been approved and uplisted from the Pink Sheets to the ...
QSAC will run a day program for adults at the center in Uniondale, which is expected to open in the spring, an executive said ...
An update from Prophase Labs ( (PRPH)) is now available. On December 29, 2025, ProPhase Labs, Inc. disclosed that it had failed to regain compliance with Nasdaq’s $1.00 minimum bid price requirement ...
Prophase Labs ( (PRPH)) just unveiled an update. ProPhase Labs, Inc. announced that it has entered into a non-binding letter of intent for a proposed reverse merger with Advanced Biological ...
Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company. Company to hold a virtual conference call ...
ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger The contemplated transaction remains subject to due ...
Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Ted Karkus, Chairman & CEO, opened by emphasizing the critical importance of shareholder voting on the company's proxy, noting, "If you do not vote for our proxy, you are putting our company in harm's ...
ProPhase Labs in discussions for strategic initiative to realize significant underlying value in the Company. Voting for Current Proxy Critically Important. Next-Phase Commercialization of BE-Smart™ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback